TY - JOUR
T1 - Human Immunodeficiency Virus Counseling, Testing, Referral, and Partner Notification Services
T2 - A Cost-Benefit Analysis
AU - Holtgrave, David R.
AU - Valdiserri, Ronald O.
AU - Gerber, A. Russell
AU - Hinman, Alan R.
PY - 1993/5/24
Y1 - 1993/5/24
N2 - Background: The Centers for Disease Control and Prevention (Atlanta, Ga) annually provides more than $100 million in funding to states, territories, and cities for the provision of human immunodeficiency virus (HIV) counseling, testing, referral, and partner notification (CTRPN) services. Given the size of this expenditure, it is important to consider the net benefits of this program activity. We compared the economic costs and benefits of publicly funded HIV CTRPN services. Methods: Standard methods for cost-benefit analysis were used. A societal perspective was employed. Major assumptions used in the base-case analysis included the following: (1) without public funding, the HIV CTRPN services would not be provided; (2) for every 100 HIV-seropositive persons identified and reached by CTRPN services, at least 20 new HIV infections are averted; and (3) for every $100 spent on direct and indirect costs of CTRPN services, approximately another $60 is spent on the ancillary costs of alerting people to HIV issues and CTRPN service availability. Sensitivity analyses were performed to explore the robustness of base-case results to these and other changes in model assumptions. Results: Under base-case assumptions, the combined direct, indirect, and ancillary costs of the CTRPN program in 1990 dollars were $188 217 600. At a 6% discount rate, the estimated economic benefits of this expenditure are $3 781 918 000. The resultant benefit-cost ratio is 20.09. Sensitivity analyses showed that the benefit-cost ratio is greater than 1 for all considered cases. Conclusions: This cost-benefit analysis strongly suggests that publicly funded CTRPN services result in a net economic gain to society.
AB - Background: The Centers for Disease Control and Prevention (Atlanta, Ga) annually provides more than $100 million in funding to states, territories, and cities for the provision of human immunodeficiency virus (HIV) counseling, testing, referral, and partner notification (CTRPN) services. Given the size of this expenditure, it is important to consider the net benefits of this program activity. We compared the economic costs and benefits of publicly funded HIV CTRPN services. Methods: Standard methods for cost-benefit analysis were used. A societal perspective was employed. Major assumptions used in the base-case analysis included the following: (1) without public funding, the HIV CTRPN services would not be provided; (2) for every 100 HIV-seropositive persons identified and reached by CTRPN services, at least 20 new HIV infections are averted; and (3) for every $100 spent on direct and indirect costs of CTRPN services, approximately another $60 is spent on the ancillary costs of alerting people to HIV issues and CTRPN service availability. Sensitivity analyses were performed to explore the robustness of base-case results to these and other changes in model assumptions. Results: Under base-case assumptions, the combined direct, indirect, and ancillary costs of the CTRPN program in 1990 dollars were $188 217 600. At a 6% discount rate, the estimated economic benefits of this expenditure are $3 781 918 000. The resultant benefit-cost ratio is 20.09. Sensitivity analyses showed that the benefit-cost ratio is greater than 1 for all considered cases. Conclusions: This cost-benefit analysis strongly suggests that publicly funded CTRPN services result in a net economic gain to society.
UR - http://www.scopus.com/inward/record.url?scp=0027253056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027253056&partnerID=8YFLogxK
U2 - 10.1001/archinte.1993.00410100057008
DO - 10.1001/archinte.1993.00410100057008
M3 - Article
C2 - 8388208
AN - SCOPUS:0027253056
SN - 0003-9926
VL - 153
SP - 1225
EP - 1230
JO - Archives of internal medicine
JF - Archives of internal medicine
IS - 10
ER -